Molecular Partners AG (NASDAQ:MOLN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...
Amgen (AMGN) Gets a Buy from Piper Sandler
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Struggles Getting Stakeholder Buy-in Slowing Gen AI Adoption
Most organizations have some type of multi-functional committee set up to evaluate generative AI applications. Those ...
Struggles Getting Stakeholder Buy-In Slow AI Adoption by In-House Counsel, Users Say
Most organizations have some type of multifunctional committee set up to evaluate generative AI applications. Those ...
BioPharma Dive15h
Novo’s Wegovy successor disappoints in second large trial
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
BAVENCIO Continues to Strengthen Its Position in the Immuno-Oncology Landscape | DelveInsight
DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...
DelveInsight Business Research, LLP: BAVENCIO Continues to Strengthen Its Position in the Immuno-Oncology Landscape | DelveInsight
With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO's market growth is driven by expanding indications and strategic partnerships. However, competition from ...